Trials / Unknown
UnknownNCT03349866
A Prospective Study of Apatinib Plus Concurrent Neoadjuvant Chemoradiotherapy for Siewert II ，III of Locally Advanced HER-2 Negative Adenocarcinoma at Gastroesophageal Junction
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 48 (estimated)
- Sponsor
- Hebei Medical University · Academic / Other
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the efficacy and safety of patients who receive concurrent neoadjuvant chemoradiotherapy for Siewert II ，III of locally advanced HER-2 negative adenocarcinoma at gastroesophageal junction.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | apatinib | apatinib：250mg qd po |
| DRUG | Capecitabine | 1000mg/m2 bid d1-14 |
| DRUG | Oxaliplatin | 130 mg/m2 Ivgtt d1 q3w |
| RADIATION | Radiotherapy | 45Gy/25f （1.8Gy/f/d，5 f/w） |
Timeline
- Start date
- 2017-11-30
- Primary completion
- 2019-11-30
- Completion
- 2020-11-30
- First posted
- 2017-11-22
- Last updated
- 2020-02-19
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03349866. Inclusion in this directory is not an endorsement.